Safety of the Malaria Vaccine Candidate, RTS,S/AS01.sub.E in 5 to 17 Month Old Kenyan and Tanzanian Children
The malaria vaccine candidate, RTS,S/AS01.sub.E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and partici...
Saved in:
Published in | PloS one Vol. 5; no. 11; p. e14090 |
---|---|
Main Authors | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Public Library of Science
29.11.2010
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | The malaria vaccine candidate, RTS,S/AS01.sub.E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14 months after dose 1 in Korogwe, Tanzania and an average of 18 months post-dose 1 in Kilifi, Kenya. Blood samples for safety monitoring of haematological, renal and hepatic functions were taken at baseline, 3, 10 and 14 months after dose 1. A total of 894 children received RTS,S/AS01.sub.E or rabies vaccine between March and August 2007. Overall, children vaccinated with RTS,S/AS01.sub.E had fewer SAEs (51/447) than children in the control group (88/447). One SAE episode in a RTS,S/AS01.sub.E recipient and nine episodes among eight rabies vaccine recipients met the criteria for severe malaria. Unsolicited AEs were reported in 78% of subjects in the RTS,S/AS01.sub.E group and 74% of subjects in the rabies vaccine group. In both vaccine groups, gastroenteritis and pneumonia were the most frequently reported unsolicited AE. Fever was the most frequently observed solicited AE and was recorded after 11% of RTS,S/AS01.sub.E doses compared to 31% of doses of rabies vaccine. The candidate vaccine RTS,S/AS01.sub.E showed an acceptable safety profile in children living in a malaria-endemic area in East Africa. More data on the safety of RTS,S/AS01.sub.E will become available from the Phase 3 programme. |
---|---|
AbstractList | The malaria vaccine candidate, RTS,S/AS01.sub.E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14 months after dose 1 in Korogwe, Tanzania and an average of 18 months post-dose 1 in Kilifi, Kenya. Blood samples for safety monitoring of haematological, renal and hepatic functions were taken at baseline, 3, 10 and 14 months after dose 1. A total of 894 children received RTS,S/AS01.sub.E or rabies vaccine between March and August 2007. Overall, children vaccinated with RTS,S/AS01.sub.E had fewer SAEs (51/447) than children in the control group (88/447). One SAE episode in a RTS,S/AS01.sub.E recipient and nine episodes among eight rabies vaccine recipients met the criteria for severe malaria. Unsolicited AEs were reported in 78% of subjects in the RTS,S/AS01.sub.E group and 74% of subjects in the rabies vaccine group. In both vaccine groups, gastroenteritis and pneumonia were the most frequently reported unsolicited AE. Fever was the most frequently observed solicited AE and was recorded after 11% of RTS,S/AS01.sub.E doses compared to 31% of doses of rabies vaccine. The candidate vaccine RTS,S/AS01.sub.E showed an acceptable safety profile in children living in a malaria-endemic area in East Africa. More data on the safety of RTS,S/AS01.sub.E will become available from the Phase 3 programme. Trial Registration ClinicalTrials.gov NCT00380393 The malaria vaccine candidate, RTS,S/AS01.sub.E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we report on the vaccine's safety and tolerability. The experimental design was a Phase 2b, two-centre, double-blind (observer- and participant-blind), randomised (1:1 ratio) controlled trial. Three doses of study or control (rabies) vaccines were administered intramuscularly at 1 month intervals. Solicited adverse events (AEs) were collected for 7 days after each vaccination. There was surveillance and reporting for unsolicited adverse events for 30 days after each vaccination. Serious adverse events (SAEs) were recorded throughout the study period which lasted for 14 months after dose 1 in Korogwe, Tanzania and an average of 18 months post-dose 1 in Kilifi, Kenya. Blood samples for safety monitoring of haematological, renal and hepatic functions were taken at baseline, 3, 10 and 14 months after dose 1. A total of 894 children received RTS,S/AS01.sub.E or rabies vaccine between March and August 2007. Overall, children vaccinated with RTS,S/AS01.sub.E had fewer SAEs (51/447) than children in the control group (88/447). One SAE episode in a RTS,S/AS01.sub.E recipient and nine episodes among eight rabies vaccine recipients met the criteria for severe malaria. Unsolicited AEs were reported in 78% of subjects in the RTS,S/AS01.sub.E group and 74% of subjects in the rabies vaccine group. In both vaccine groups, gastroenteritis and pneumonia were the most frequently reported unsolicited AE. Fever was the most frequently observed solicited AE and was recorded after 11% of RTS,S/AS01.sub.E doses compared to 31% of doses of rabies vaccine. The candidate vaccine RTS,S/AS01.sub.E showed an acceptable safety profile in children living in a malaria-endemic area in East Africa. More data on the safety of RTS,S/AS01.sub.E will become available from the Phase 3 programme. |
Audience | Academic |
Author | Lang, Trudie Gould, Jayne Drakeley, Chris J Riley, Eleanor M Olivier, Aurélie Abdul, Omar Njuguna, Patricia Benns, Sarah Leach, Amanda Vekemans, Johan Malabeja, Anangisye Gesase, Samwel Cohen, Joe Bejon, Philip Lemnge, Martha M Savarese, Barbara Olomi, Raimos Ismael, Sadiki Olotu, Ally Msham, Salum Guerra, Yolanda Ballou, W. Ripley Lievens, Marc Hallez, Karin Mturi, Neema Malle, Lincoln Awuondo, Ken O Marsh, Kevin von Seidlein, Lorenz Lusingu, John Dekker, Denise Villafana, Tonya |
Author_xml | – sequence: 1 fullname: Lusingu, John – sequence: 2 fullname: Olotu, Ally – sequence: 3 fullname: Leach, Amanda – sequence: 4 fullname: Lievens, Marc – sequence: 5 fullname: Vekemans, Johan – sequence: 6 fullname: Olivier, Aurélie – sequence: 7 fullname: Benns, Sarah – sequence: 8 fullname: Olomi, Raimos – sequence: 9 fullname: Msham, Salum – sequence: 10 fullname: Lang, Trudie – sequence: 11 fullname: Gould, Jayne – sequence: 12 fullname: Hallez, Karin – sequence: 13 fullname: Guerra, Yolanda – sequence: 14 fullname: Njuguna, Patricia – sequence: 15 fullname: Awuondo, Ken O – sequence: 16 fullname: Malabeja, Anangisye – sequence: 17 fullname: Abdul, Omar – sequence: 18 fullname: Gesase, Samwel – sequence: 19 fullname: Dekker, Denise – sequence: 20 fullname: Malle, Lincoln – sequence: 21 fullname: Ismael, Sadiki – sequence: 22 fullname: Mturi, Neema – sequence: 23 fullname: Drakeley, Chris J – sequence: 24 fullname: Savarese, Barbara – sequence: 25 fullname: Villafana, Tonya – sequence: 26 fullname: Ballou, W. Ripley – sequence: 27 fullname: Cohen, Joe – sequence: 28 fullname: Riley, Eleanor M – sequence: 29 fullname: Lemnge, Martha M – sequence: 30 fullname: Marsh, Kevin – sequence: 31 fullname: Bejon, Philip – sequence: 32 fullname: von Seidlein, Lorenz |
BookMark | eNqNkE1rAjEQhkOxULX9Bz0ECoWCuyab7NdRxLZSRXCtVxmzWTcSs8VkofbXN9AeFHooc5iv531hpoc6pjESoXtKQspSOtw37dGADj_8OCSEcpKTK9SlOYuCJCKsc1bfoJ61e0JiliVJF-kCKulOuKmwqyWeg4ajArwGIZSReAymVCU4OcDLVTEohqOC0NC223CClcExdg2mKZ43xtV4oUv8Js0JDPYyvALzBUb5blwrXR6luUXXFWgr735zH70_T1bj12C2eJmOR7NgR5OEBzFwSiVJBMsExJBJHrOKMpFHkEDKsgpKFuUMWCaz0t-fxfk2YVXKheB-VbI-evjx3YGWG2Wqxh1BHJQVmxH3BlHOI-6p8A_KRykPSvhXVsrPLwRPFwLPOPnpdtBau5kWy_-zi_Ul-3jG1hK0q22jW6caY8_Bb5XKk78 |
ContentType | Journal Article |
Copyright | COPYRIGHT 2010 Public Library of Science |
Copyright_xml | – notice: COPYRIGHT 2010 Public Library of Science |
DBID | IOV ISR |
DOI | 10.1371/journal.pone.0014090 |
DatabaseName | Gale In Context: Opposing Viewpoints Science in Context |
DatabaseTitleList | |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Sciences (General) |
EISSN | 1932-6203 |
ExternalDocumentID | A473829424 |
GroupedDBID | --- 123 29O 2WC 3V. 53G 5VS 7RV 7X2 7X7 7XC 88E 8AO 8C1 8CJ 8FE 8FG 8FH 8FI 8FJ A8Z AAFWJ ABDBF ABIVO ABJCF ABUWG ACGFO ACIHN ACIWK ACPRK ADBBV ADRAZ AEAQA AENEX AFKRA AFPKN AFRAH AHMBA ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS APEBS ARAPS ATCPS BAWUL BBNVY BBORY BCNDV BENPR BGLVJ BHPHI BKEYQ BPHCQ BVXVI BWKFM CCPQU CS3 D1I D1J D1K DIK DU5 E3Z EAP EAS EBD EMOBN ESTFP ESX EX3 F5P FPL FYUFA GROUPED_DOAJ GX1 HCIFZ HH5 HMCUK HYE IAO IEA IHR IHW INH INR IOV IPNFZ IPY ISE ISR ITC K6- KB. KQ8 L6V LK5 LK8 M0K M1P M48 M7P M7R M7S M~E NAPCQ O5R O5S OK1 P2P P62 PATMY PDBOC PIMPY PQQKQ PROAC PSQYO PTHSS PYCSY RIG RNS RPM SV3 TR2 UKHRP WOQ WOW ~02 ~KM |
ID | FETCH-LOGICAL-g1664-5a411e06c38ca5a8e453f13c92a6a738fad3293a38e8d371859b63f74cc4ad3d3 |
IEDL.DBID | M48 |
ISSN | 1932-6203 |
IngestDate | Tue Nov 19 21:09:34 EST 2024 Tue Nov 12 22:57:04 EST 2024 Thu Aug 01 20:23:54 EDT 2024 Thu Aug 01 20:36:49 EDT 2024 Tue Aug 20 22:13:16 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 11 |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-g1664-5a411e06c38ca5a8e453f13c92a6a738fad3293a38e8d371859b63f74cc4ad3d3 |
PageCount | e14090 |
ParticipantIDs | gale_infotracmisc_A473829424 gale_infotracacademiconefile_A473829424 gale_incontextgauss_ISR_A473829424 gale_incontextgauss_IOV_A473829424 gale_healthsolutions_A473829424 |
PublicationCentury | 2000 |
PublicationDate | 20101129 |
PublicationDateYYYYMMDD | 2010-11-29 |
PublicationDate_xml | – month: 11 year: 2010 text: 20101129 day: 29 |
PublicationDecade | 2010 |
PublicationTitle | PloS one |
PublicationYear | 2010 |
Publisher | Public Library of Science |
Publisher_xml | – name: Public Library of Science |
SSID | ssj0053866 |
Score | 2.0212684 |
Snippet | The malaria vaccine candidate, RTS,S/AS01.sub.E, showed promising protective efficacy in a trial of Kenyan and Tanzanian children aged 5 to 17 months. Here we... |
SourceID | gale |
SourceType | Aggregation Database |
StartPage | e14090 |
SubjectTerms | Gastroenteritis Malaria Malaria vaccines Medical research Vaccination Vaccines |
Title | Safety of the Malaria Vaccine Candidate, RTS,S/AS01.sub.E in 5 to 17 Month Old Kenyan and Tanzanian Children |
Volume | 5 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV1NaxsxEBUhufRSmqalaRJ3CIW2ELnWSitrD6U4xiEtOCleO-RmZrVSGjDrxt5A_e872ighhqb0rKf9GGmkN0hvhrH3wga5JmouTVFy5YTjqNBzWXrtbVaIwgQ18vBMn07U98v0coPd12yNBlz-NbQL9aQmi1n7983qKzn8l6ZqQ1fcd2r_mleu3SSMySiI30pobwyXvIbq4VyBvLs5vQysheukI6OY7qmnxHX60Y5z8oI9j1QRendju802XPWSbUdnXMLHmDH60w6b5ehdvYK5B-JzMET6p2uEC7Th2Bz6QboSIvsjGI3zo_xzL--IpvjVAK4rSKGeg-gCuXf9E85nJdDqu8IKqBuMiTtiRXMI-lH2_YpNTgbj_imPZRT4ldBa8RSVEK6jrTQWUzROpdILabMENXal8VhK2vRRGmdKsoRJs0JL31XWKmoq5Wu2WZFR3jDQNI7EKQjjiHloUcjSZsYnLkkLLDK7y94Fe03vNJwPzjPtKXpPkqlE7bLDBhFST1ThbssV3i6X02_nF_8BykdroA8R5Of1Ai1GPQF9aUhptYbcX0OSA9lHzW__3bzHnjU3BoTgSbbPNuvFrTsgIlIXLbZ1PDj7MWo1gXyrmWl_ABqb25o |
link.rule.ids | 314,780,784,864,2221,24318,27924,27925 |
linkProvider | Scholars Portal |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Safety+of+the+Malaria+Vaccine+Candidate%2C+RTS%2CS%2FAS01.sub.E+in+5+to+17+Month+Old+Kenyan+and+Tanzanian+Children&rft.jtitle=PloS+one&rft.au=Lusingu%2C+John&rft.au=Olotu%2C+Ally&rft.au=Leach%2C+Amanda&rft.au=Lievens%2C+Marc&rft.date=2010-11-29&rft.pub=Public+Library+of+Science&rft.issn=1932-6203&rft.eissn=1932-6203&rft.volume=5&rft.issue=11&rft.spage=e14090&rft_id=info:doi/10.1371%2Fjournal.pone.0014090&rft.externalDocID=A473829424 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1932-6203&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1932-6203&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1932-6203&client=summon |